All In Biotech

NDA 017532 · Sanofi Aventis US

Diabeta

Glyburide · Oral · Sulfonylurea

Last checked: Nov 20, 2026Latest source record: Jan 11, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1984

May 1, 1984

Approved uses

1

Original approval plus efficacy supplements

Registered trials

119

30 Phase 3, 2 recruiting

FAERS reports

24,129

15,175 serious, 2,143 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 1, 2021.

INDICATIONS AND USAGE Glyburide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 1, 1984 Original approval · Type 5 - New Formulation or New Manufacturer
3 products under this application
  • DIABETA · GLYBURIDE 2.5MG · TABLET, ORAL · Prescription · TE AB2
  • DIABETA · GLYBURIDE 5MG · TABLET, ORAL · Prescription · TE AB2
  • DIABETA · GLYBURIDE 1.25MG · TABLET, ORAL · Prescription · TE AB2

Clinical trials

Interventional ClinicalTrials.gov studies with "Glyburide" as an intervention, any sponsor and status, largest first.

All 119 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased3,044
  • nausea2,043
  • weight decreased1,546
  • drug ineffective1,431
  • diarrhoea1,311
  • dizziness1,220
  • hypoglycaemia1,210
  • blood glucose decreased1,167
  • fatigue1,158
  • dyspnoea1,099
  • asthenia1,052
  • vomiting1,046

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,141
20051,216
20061,948
20071,899
20081,503
20091,225
20101,477
20111,813
20121,497
20131,199
20141,133
20151,454
20161,172
2017891
2018905
2019812
2020686
2021528
2022432
2023426
2024303
2025267
2026201

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Aug 10, 2026

    Diabeta, Tablet, 5 mg (NDC 0093-9364-01). A business decision was made to discontinue manufacture of the drug.

  • To Be Discontinued · updated Aug 10, 2026

    Diabeta, Tablet, 1.25 mg (NDC 0093-9477-53). A business decision was made to discontinue manufacture of the drug.

  • To Be Discontinued · updated Aug 10, 2026

    Diabeta, Tablet, 2.5 mg (NDC 0093-9433-01). A business decision was made to discontinue manufacture of the drug.

  • To Be Discontinued · updated Aug 10, 2026

    Diabeta, Tablet, 5 mg (NDC 0093-9364-10). A business decision was made to discontinue manufacture of the drug.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 265 on PubMed

Sponsor: Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.